Search

everythinglearnresearchcommunity

for

Search:↓

Blocking YAP/TAZ could be a new way to treat skin cancer.

Type I interferons may help treat skin issues in lupus and dermatomyositis.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

FK506 may stimulate hair growth when applied to the skin.

IFN-γ and IL-2 are important for T cell activation in hair loss in mice.

Intralesional cidofovir may be a viable alternative treatment for SCC.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

MK-5108 is safe and shows potential against tumors, especially alone.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

K10 may not prevent tumors as previously thought and might increase benign tumor risk.

JAK inhibitors may help treat both alopecia areata and vitiligo, but more research is needed.

Compounds from Pterocarpus indicus may help treat benign prostatic hyperplasia by stopping cell growth.

Potassium channel activators like nicotinamide and minoxidil might help treat solid tumors.

Gefitinib can cause rare scarring hair loss.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

hsa-miR-193a-5p may help diagnose and treat alopecia areata.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

A blood pressure drug, diltiazem, may also help treat influenza.

The research suggests new treatments for skin cancer could target specific cell growth pathways.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

AIMP1 can boost hair growth by increasing stem cell activity.

Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Ipilimumab can cause various adverse events in elderly patients, especially affecting the gastrointestinal and endocrine systems.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

Skin reactions from cancer treatments might predict how well the treatments work.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Upadacitinib effectively treats pyoderma gangrenosum.

Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.